BlueCross BlueShield
Federal Employee Program

AYVAKIT
(avapritinib)

Pre - PA Allowance

None

Prior-Approval Requirements

Age 18 years of age or older

Diagnoses

Patient must have **ONE** of the following:

1. Unresectable or metastatic gastrointestinal stromal tumor (GIST)
   a. Platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations
2. Advanced systemic mastocytosis (AdvSM), including aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL)
   a. Platelet count ≥ 50 x 10^9/L
3. Indolent Systemic Mastocytosis (ISM)
   a. Platelet count ≥ 50 x 10^9/L

AND ALL of the following:

a. Prescriber agrees to monitor for intracranial hemorrhage and CNS adverse reactions
b. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Ayvakit and for 6 weeks after the last dose
c. Males with female partners of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Ayvakit and for 6 weeks after the last dose

Prior - Approval Limits

Quantity 90 tablets per 90 days

Duration 12 months

Prior – Approval *Renewal* Requirements

AYVAKIT
(avapritinib)

Age 18 years of age or older

Diagnoses

Patient must have **ONE** of the following:

1. Gastrointestinal stromal tumor (GIST)
    a. **NO** disease progression or unacceptable toxicity
2. Advanced systemic mastocytosis (AdvSM), including aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL)
    a. Platelet count ≥ 50 x 10^9/L
    b. **NO** disease progression or unacceptable toxicity
3. Indolent Systemic Mastocytosis (ISM)
    a. Platelet count ≥ 50 x 10^9/L

AND ALL of the following:

a. Prescriber agrees to monitor for intracranial hemorrhage and CNS adverse reactions
b. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Ayvakit and for 6 weeks after the final dose
c. Males with female partners of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Ayvakit and for 6 weeks after the last dose

Prior - Approval *Renewal* Limits

Same as above